Avsnitt
-
Saknas det avsnitt?
Listen to a soundcast of the October 21st and 25th 2022, FDA approvals of Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and Tecvayli (teclistamab-cqyv) for relapsed or refractory multiple myeloma.
Saknas det avsnitt?